Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Walter in HK who wrote (2862)	7/26/1999 8:34:00 AM
From: Glenn Petersen	Read Replies (1) \| Respond to of 4140

Responses to frequently answered questions posted on the SNRS web site: biz.yahoo.com Monday July 26, 7:16 am Eastern Time Company Press Release Sunrise Technologies International Inc. Responds to Frequently Asked Questions FREMONT, Calif.--(BW HealthWire)--July 26, 1999--Sunrise Technologies International, Inc. (Nasdaq:SNRS - news) -- today responded to frequently asked questions from investors regarding its regulatory and business-development strategies. Those responses can be found on the Company's website at www.sunrise-tech.com. ''The questions and answers posted on our website are part of our stated desire to continue to be accessible to those who want to know about and understand our Company,'' said C. Russell Trenary III, President and CEO of Sunrise Technologies. The Company indicated that it will update this document periodically as additional information is available. Founded in 1987, the Company produces and markets high technology products revolutionizing treatment methods in eye care. The Company develops Holmium laser-based systems, which utilize a patented process for shrinking collagen developed by Dr. Bruce Sand (the ''Sand Process'') in correcting ophthalmic conditions. These Systems (1) incorporate a non-contact simultaneous application for correction of hyperopia (farsightedness), presbyopia (loss of focus due to natural aging), and overcorrection resulting from PRK and LASIK treatments for myopia. The system is currently in use in Europe and the Americas, and is in clinical trials in the United States. Except for historical information, this news release contains certain forward-looking statements that involve risk and uncertainties which may cause actual results to differ materially from the statements made, including market potential, regulatory clearances, business growth and other risks listed from time to time in the Company's Securities and Exchange Commission (SEC) filings. These forward-looking statements represent the Company's judgment, as of the date of this release, and the Company disclaims any intent or obligation to update these forward-looking statements.•(1) Caution -- Investigational Device: Federal law restricts this device to investigational use in the U.S. Internet users can access Sunrise's World Wide Web site at sunrise-tech.com. ------------------------------------------------------------------------ Contact: Sunrise Technologies International, Inc. Susan Lorigan, 510/623-9001 Ed Coghlan, 510/771-2399